co-Chief Exec at Myeloma Patients Europe. Interest in health policy and medicines access plus the occasional tweet about Scotland and travel. Views mine.
We asked patients, carers, clinicians, researchers and stakeholders about the biggest challenges in #myeloma and how MPE can make a difference. Their insights helped shape our new Strategic Goals 2025 – 2030. These will drive our work in the coming years.
https://t.co/Qemw87rqXI
We are looking for a new consultant colleague (10 PA, substantive NHS post). Great opportunity for anyone with an interest in myeloma who wants to join an academic centre. https://t.co/vvIAZhIkv6
MPE Co-CEO, Katie Joyner, spoke at @EMN_EuMMnet's 5th annual meeting, highlighting the importance of empowering European patients to access clinical trial information.
¨Patients deserve accurate, comprehensive information for informed discussions with healthcare teams.¨
ODAC unanimously votes in favor of using #MRD as an early endpoint for accelerated approval in #myeloma trials
This was a huge team effort for more than 8 years and with the generosity of unprecedented data sharing from many investigators around the world. Thank you all!
#mmsm
@US_FDA's Oncologic Drugs Advisory Committee (ODAC) recognises Minimal Residual Disease (MRD) as an accepted endpoint for accelerated approval in myeloma.
Read more information here: https://t.co/7WQyLSDCLs
@OncLive#myeloma#MRD
Today, US FDA held an ODAC meeting to debate MRD as an endpoint to support accelerated approval in #myeloma clinical trials. Two groups (@SylvesterCancer and i2TEAMM) presented retrospective data from clinical trials that measured MRD. Final vote was 12-0 in favor.
.@EMA_News CHMP gives positive recommendation on #CART-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory #myeloma
https://t.co/Rx9nBSSx9c
Commissioner @SKyriakidesEU highlights #EUCancerPlan progress, including the first EU network linking National Comprehensive Cancer Centres in every MS, but discussions show more work remains to tackle inequalities, among other issues.
#WorldCancerDay
EU funded project @ASCERTAIN_EU , of which MPE is a partner, is in its second year! The Consortium meeting ended yesterday with presentations on the project’s progress, followed by discussions and suggestions from partners and advisory board members
https://t.co/e0JRUdM0Qd
Led by @EHA_hematology, with the involvement of MPE, the article "Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials" is now published! An important step in improving the collection of #PROs.
https://t.co/vGgoJ2NHq8
MPE is a partner in an exciting new @HorizonEU project called #CERTAINTY, which explores the role of virtual twins in CAR-T and personalised #myeloma care.
You can explore further information about the project here:
#ASH23 has already started for the MPE team! Ready to learn about the more important updates on #myeloma and #ALamyloidosis and meet friends and colleagues
Participate in our myeloma survey on shared decision-making! Share your experiences to improve communication between patients and healthcare professionals.
Available in English, Hebrew, Slovenian, German, Spanish, French, Dutch, and Swedish
https://t.co/tMvYWBkqKJ
Congratulations to our colleagues at @KU_Leuven, who will present a poster today at @ISPORorg 2023 on the work MPE and our Israeli member AMEN have been supporting on shared decision making.
https://t.co/elWm9SsGHP
📣Are you interested in leading an organisation with the mission of advocating for HIV patients? @EATGx is hiring a new Executive Director!
EATG represents a network of more than 150 members, from 45 countries in Europe.
Apply below!
👉https://t.co/LCGbLrlMJs